Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$0.04 0.00 (-2.44%)
2/9/2010 3:37 PM

Nanogen, Inc. (NGEN.PK)

CAPS Rating:
***

The Company is in the business of developing, manufacturing, and selling diagnostic products.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

NGEN.PK doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Nanogen, Inc. At A Glance

Current Price: $0.04
Last Trade Time: 2/9/2010 3:37 PM
Open: $0.03
Previous Close: $0.04
Daily Range: $0.03 - $0.04
52-Week Range: $0.01 - $0.21
Volume: 42,551
Market Cap: $3.45M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

NGEN.PK VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Nanogen, Inc. (NGEN.PK)

Avatar HonestK (96.37) Submitted: 10/31/06 11:49 AM

All the hypesters have left the building.

Time to quietly move in. Shhh!

(Yeah right, like my little accumulation is going to catch the market's attention!)

Now, just sit back and let those folks continue to grow their patent portfoilio, product line and sales.

Replies: 2 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 13 :   1 2 3 Next »

Show Pitch Replies

Recs

0

 (NGEN.PK)

Avatar vagan (< 20) Submitted: 4/17/07 11:15 AM : Outperform Start Price: $2.01 NGEN.PK Score: -75.00

This stock is currently underpriced, has begun to rebuild a market, and will recover significantly over the next several years

Report this Post Replies: 2 | Reply | Permalink

Recs

0

 (NGEN.PK)

Avatar ndubueze (< 20) Submitted: 4/04/07 11:25 PM : Outperform Start Price: $1.68 NGEN.PK Score: -76.51

this one's definetly flying off the top

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (NGEN.PK)

Avatar golfstudio (< 20) Submitted: 2/22/07 2:43 AM : Outperform Start Price: $1.60 NGEN.PK Score: -75.42

Undervalued. Finalyy showing real growth and have a great product line with many patents.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (NGEN.PK)

Avatar NetscribeNanoTch (63.34) Submitted: 1/19/07 8:17 AM : Outperform Start Price: $1.79 NGEN.PK Score: -77.60

Nanogen, Inc. provides advanced human molecular diagnostic products to researchers, healthcare professionals and patients worldwide with improved methods and tests to investigate, predict, diagnose and ultimately help treat diseases. The company has diagnostic technologies that focus on the identification of the nucleic acid sequences, gene variations, and gene expressions associated with genetic conditions and infectious diseases. It has four categories of products, which include instrumentation, reagents, test kits, and custom assays.

The company has been consistently acquiring several businesses over the last two-and-a-half years. This has helped the company to build a broad platform for the emerging personalized medicine market. Along with these strategic acquisitions the company is also performing well, which can be seen from 19% revenue growth in the recent quarter. Its gross margin dollars have been increasing on a faster pace and should continue to climb as revenue continues to grow. The company is also eying to improve the EBITDA by reducing expenses. In line with this approach the company has announced that it will reduce the head count by 15% in coming several months.

The company is also trying to improve its liquidity position by entering into various deals such as the recent deal in which the company sold an expected future stream of royalty payments from Applied Biosystems. Adding to this it is also expected that Fisher Scientific will support up to $10 million of collaborative research at Nanogen during 2007 and 2008. This will fund their Research and Development activities, a benefit to both companies without causing the company to issue additional shares of stock.

The company is in a better position to capture the opportunity presented by the potentially large healthcare services market which is evident by its recent results. It is expected the company’s revenue will grow at a healthy pace due to market acceptance of their products and funded research activities, which will help its stock to achieve positive growth.

Report this Post Replies: 3 | Reply | Permalink

Recs

0

 (NGEN.PK)

Avatar pvandevelde1965 (< 20) Submitted: 12/31/06 5:45 AM : Outperform Start Price: $1.86 NGEN.PK Score: -77.85

Strong growth - a bit forgotten by Wall Street

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 13 :   1 2 3 Next »

Wall Street

There are no Wall Street tracker picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD04 328ms